EUVIMEDEUVIMED entdecken
Crossref

Rethinking HIV treatment: How non‐ integrase strand regimens may hold the key to better immune health

Bogusz Aksak-Wąs iD, Karolina Skonieczna-Żydecka, Miłosz Parczewski, Rafał Hrynkiewicz, Filip Lewandowski, Karol Serwin, Kaja Mielczak, Franciszek Lenkiewicz, Paulina Niedźwiedzka-Rystwej

HIV Medicine · 2025-06 · 26 (6) · 879-887

DOI: 10.1111/hiv.70020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HIV Medicine, online erschienen am 28.03.2025. Verfasst von Bogusz Aksak-Wąs und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious, Tropical Diseases and Acquired Immunodeficiency, Pomeranian Medical University in Szczecin, Szczecin, Poland. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents, HIV Integrase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Polish National Science Centre, Polish AIDS Society (PTN AIDS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

HIV outcome changed drastically with antiretroviral (ARV) therapy, especially after the introduction of second‐generation integrase strand transfer inhibitors (INSTIs). Despite these advances, however, chronic immune activation and exhaustion, marked by programmed cell death 1 (PD‐1) and programmed death ligand 1 (PD‐L1) upregulation, persist in patients. This study investigates the impact of various ARV regimens on these immune exhaustion markers in newly diagnosed HIV patients over 12 months, taking into consideration cardiovascular risk.

Methods

This study included 58 newly diagnosed patients with HIV at Pomeranian Medical University, Szczecin, Poland. Participants received ARV regimens classified as INSTI + tenofovir alafenamide, INSTI + tenofovir disoproxil fumarate, or non‐INSTI‐based (VARIA). Flow cytometry was used to assess PD‐1 and PD‐L1 expression on CD3+, CD3+CD4+, CD3+CD8+ and CD19+ lymphocytes. Statistical analyses included Wilcoxon paired tests, Kruskal–Wallis tests and multivariate regression, with validation through residual analysis and linear discriminant analysis (LDA).

Results

INSTI‐based regimens were linked to higher PD‐1 expression on CD3+ and CD3+CD4+ lymphocytes, indicating increased immune exhaustion. Conversely, non‐INSTI regimens were associated with lower PD‐1 levels, suggesting better retention of immune function. A positive correlation between cardiovascular risk a prediction model to estimate 10‐year fatal and non‐fatal cardiovascular disease (SCORE2) and PD‐1 expression was observed. However, the modest explanatory power of the models suggests variability in the effects of different ARV regimens.

Conclusion

This study challenges the assumption that INSTI‐based ARV regimens are universally superior, suggesting that non‐INSTI therapies may better preserve immune function by reducing PD‐1 expression. These findings highlight the potential benefits of non‐INSTI regimens in improving long‐term clinical outcomes in HIV treatment, warranting further research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsAnti-HIV AgentsHIV Integrase InhibitorsHumansMaleFemaleAdultMiddle AgedB7-H1 AntigenProgrammed Cell Death 1 ReceptorPolandTenofovir

Stichwörter der Autor:innen

HIVNNRTIPD‐1SCORE2

Substanzen

B7-H1 AntigenProgrammed Cell Death 1 ReceptorAnti-HIV AgentsCD274 protein, humanPDCD1 protein, humanTenofovirHIV Integrase Inhibitors

Autor:innen und Institutionen

  • Department of Infectious, Tropical Diseases and Acquired Immunodeficiency, Pomeranian Medical University in Szczecin, Szczecin, Poland.
  • Department of Biochemical Science, Pomeranian Medical University in Szczecin, Szczecin, Poland.
  • Institute of Biology, University of Szczecin, Szczecin, Poland.
  • Center for Experimental Immunology and Immunobiology in Infectious Diseases and Cancer, University of Szczecin, Szczecin, Poland.

ORCID-Profile: Bogusz Aksak-Wąs

Förderung

  • Polish National Science Centre
  • Polish AIDS Society (PTN AIDS)

Zitieren

APA

Aksak-Wąs, B., Skonieczna-Żydecka, K., Parczewski, M., Hrynkiewicz, R., Lewandowski, F., Serwin, K., Mielczak, K., Lenkiewicz, F., & Niedźwiedzka-Rystwej, P. (2025). Rethinking HIV treatment: How non‐ integrase strand regimens may hold the key to better immune health. HIV Medicine, 26(6), 879-887. https://doi.org/10.1111/hiv.70020

Vancouver

Aksak-Wąs B, Skonieczna-Żydecka K, Parczewski M, Hrynkiewicz R, Lewandowski F, Serwin K, et al. Rethinking HIV treatment: How non‐ integrase strand regimens may hold the key to better immune health. HIV Medicine. 2025;26(6):879-887. doi:10.1111/hiv.70020

BibTeX
@article{AksakWs2025,
  author = {Aksak-Wąs, Bogusz and Skonieczna-Żydecka, Karolina and Parczewski, Miłosz and Hrynkiewicz, Rafał and Lewandowski, Filip and Serwin, Karol and Mielczak, Kaja and Lenkiewicz, Franciszek and Niedźwiedzka-Rystwej, Paulina},
  title = {Rethinking HIV treatment: How non‐ integrase strand regimens may hold the key to better immune health},
  journal = {HIV Medicine},
  year = {2025},
  volume = {26},
  number = {6},
  pages = {879--887},
  doi = {10.1111/hiv.70020}
}
Kostenlos starten →